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(–)-Cytisine: Access to a Stereochemically Defined and 
Functionally Flexible Piperidine Scaffold 
Worawat Niwetmarin, Hugo Rego Campello, Hazel A. Sparkes, Varinder K. Aggarwal and Timothy 
Gallagher* 
N-Benzyl cytisine undergoes an efficient C(6)-N(7) cleavage via directed C(6) lithiation, borylation and oxidation to provide 
a “privileged” heterocyclic core unit comprising a highly functionalised, cis-3,5-disubstituted piperidine in enantiomerically 
pure form.  The potential offered by this unit as a means to explore chemical space has been evaluated and methods have 
been defined (and illustrated) that allow for selective manipulation of N(1), C(3’), and the pyridone N.  The pyridone core 
can also be diversified via bromination (at C(3’’) and C(5’’)) which is complementary to direct C-H activation based on Ir-
catalyzed borylation to provide access to C(4’’).  The use of a boronate-based 1,2-migration as an alternative trigger to 
mediate C(6)-N(7) cleavage of cytisine was evaluated but failed. However, the stability of the intermediate boronate opens 
a new pathway for the elaboration of cytisine itself using both Matteson homologation and Zweifel olefination. 
Introduction  
Contemporary “small molecule” drug discovery relies on a 
variety of strategies to both identify and develop “hits” into 
leads and then drug candidates. Clearly, the ability to define and 
explore novel “chemical space” plays a key role in terms of 
generating (and then protecting to enable further exploitation) 
intellectual property.1  For many years natural products 
provided a valued entry to enable structural variation but 
pharmaceutical industry interest in this area has, at points, 
waned in favor of, for example, combinatorial chemistry and 
related approaches as the preferred means by which to achieve 
molecular diversity.2  However, the enormous structural 
variation associated with natural products has, regardless, 
continued to provide a source of inspiration (and a guide) that 
has led to the development of, for example, diversity-oriented 
and “chemical genetics” approaches to lead discovery.3 
Natural products, which are often available in enantiomerically 
pure form and may contain multiply stereogenic centers, do 
provide one important starting point for a diversity-oriented 
approach to drug discovery.  Several natural products or core 
components of natural products, such as 
1-O-acetylbritannilactone4a and maslinic acid4b have found 
application in this area (Scheme 1).   
Taking this further, an ability to harness further the reactivity of 
a readily available natural product to widen the reach of the 
structural diversity available is well exemplified by Schwarz’s 
work on -santonin.5  Here, both the natural product 1 and a 
readily available variant 2 (available from 1 by acid-catalysed 
rearrangement) provided analogues of both of these related 
scaffolds that were explored as inhibitors of 5-lipoxygenase. 
Scheme 1 Top: Example of natural products providing a 
functionalised core scaffold.  Bottom: derivatisation of 
-santonin 1. 
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The role of “privileged scaffolds” serves as a further focus in this 
area, with many being based on or incorporating a heterocyclic 
core.  Of these, piperidines are especially widely distributed and 
are found in a large number of bioactive and important 
pharmaceutical compounds.6  Our work has focussed on 
developing new and stereochemically-defined heterocyclic 
scaffolds based, in part, on nitrogen-based natural products 
that incorporate piperidine moieties.7  These include 
coerulescine 3, which led to the development of a range of 
stereochemically-defined spirocyclic bis(azacycles), such as the 
piperidine and the pyrrolidine-containing units 4 and 5.8  Each 
of these spirocyclic scaffolds (within which the individuals 
enantiomers are accessible) offers three discrete 
functionalisation sites:  two secondary but readily differentiated 
amines (blue and purple), and a primary alcohol (red), all of 
which are distributed across a spatially distinctive spirocyclic 
core. 
 
We have, more recently, aimed to extend this chemistry by 
evaluating the opportunity to “release” a stereochemically 
complex and functionally-flexible piperidine core unit from a 
readily accessible precursor; this is related to but distinctive 
from the concept outlined in Scheme 1.  Our initial focus for this 
has been the development of the chemistry based on (–)-
cytisine 6, a readily accessible lupin alkaloid from Laburnum 
anagyroides,9 and the results of this work are summarised in 
this paper. 
(-)-Cytisine, which is a partial agonist of the nicotinic 
acetylcholine receptor (the high affinity nicotine binding site in 
brain), is marketed (as Tabex®) within Eastern and Central 
Europe for smoking cessation.10,11 While that specific nicotinic 
profile may not be required (or desired), we recognised that 
cytisine 6 offered a readily available starting point from which 
to construct a series of structurally diverse libraries if, for 
example, the piperidine unit (coded blue) could be “released” 
from within the tricyclic heterocyclic core of 6.  
Cytisine 6 has already inspired a diversity-oriented synthesis 
approach to novel inhibitors of Bcl-2 and there has been 
extensive studies associated with the substitution of cytisine 
itself, driven largely by attempts to develop novel nicotinic 
ligands.12  Of particular relevance to the work described here 
are the studies of Rouden and co-workers on the site-specific 
lithiation of N-acylated cytisines; this is illustrated by an N to C 
acyl transfer to functionalise at C(6) (Scheme 2).13 We had 
reasoned that using an appropriate electrophile, 
functionalisation of C(6) would allow for cleavage of the 
C(6)-N(7) link, and release of an intact piperidine unit.  This was 
achieved as shown in Scheme 2 by C(6)-lithiation (via 8) and (in 
situ) silylation of (–)-N-methylcytisine (caulophylline) 7 followed 
by C-Si  C-O oxidation followed by reduction.  This sequence 
demonstrated the underlying concept by liberating the 
piperidine moiety (highlighted in blue) and provided a direct 
entry to the related lupin piperidine alkaloid (+)-kuraramine 11 
in 18% overall yield from (-)-7.14 
 
Scheme 2. Top: C(6) Lithiation triggering N(3)C(6) acyl 
migration (Rouden et al13).  Bottom: C(6) Oxidative 
functionalisation of N-methylcytisine 7; a biomimetic synthesis 
of (+)-kuraramine 11 (Gallagher et al14). 
 
However, this initial solution involved the use of a silyl 
electrophile which necessitated a stoichiometric amount of a 
mercury-based oxidant to achieve the key Fleming-Tamao 
oxidative cleavage (9 hemiaminal 10; overall 26% from 7); 
alternatives to Hg(II) were evaluated but failed (see below).  This 
issue alone, notwithstanding the modest yields, presents a clear 
block to any more general use of this approach to access a 
versatile heterocyclic (piperidine) scaffold or in a fragment-
based approach to drug discovery. Given the goal of exploiting 
an ability to fragment cytisine, alongside the recognised 
importance of the piperidine scaffold within medicinal 
chemistry and a consequential ability to access efficiently 
differentiated and enantiomerically-pure piperidine-based 
libraries, this key synthetic obstacle had to be addressed.  
In this paper, we describe a much more user-friendly solution to 
the cleavage of the C(6)-N(7) bond of cytisine shown in Scheme 
2, which also offers access to the piperidine core with flexibility 
around the secondary amine protecting group.  Further, the 
chemistry we have now developed avoids any heavy metals and 
is significantly more efficient and scalable. We have not 
explicitly focussed on a specific medicinal chemistry target, 
rather we have aimed to exemplify how the piperidine core can 
be both accessed and manipulated at various sites to provide 
access to a wide range of functional variants. The scope of this 
chemistry is outlined, in terms of the sites that become 
accessible, by general structure A and the issues around 
accessing each of these sites serves as the focus of this paper. 
The positions immediately accessible for derivatisation include 
two differentiated nitrogen centres (N(1) and N(1’’) in the 
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piperidine and the pyridone moieties respectively); an ability to 
manipulate the C(3′) methylene unit; further functionalisation 
of the pyridone moiety via either electrophilic bromination 
(which occurs predominantly at C(3″)) or, and of more utility 
and novelty, Ir-catalysed C-H activation which selectively 
targets C(4″). 
This program has been driven in part by an increased awareness 
of the power and potential within medicinal chemistry 
associated with cost effective in silico assessment of ligands 
against protein targets of interest.  Indeed, the goal would be to 
enable a full evaluation of the “effectiveness” of a ligand or 
family of ligands prior to embarking on an expensive program of 
chemical synthesis and evaluation by biological assay.15  As the 
dependability of these in silico methods increases so will their 
value as a reliable predictive tool.  This would then enable the 
routine application of in silico prioritization of putative ligands 
as an early step in lead selection.  It is likely that this, in turn, 
will lead to a rebalancing of the current reliance on existing 
library collections (i.e. physical samples) towards evaluating 
synthetic methodologies that offer opportunities to access as-
yet-unexplored ligands.16 Those methodologies must, 
necessarily, encompass versatile, drug-like scaffolds such as A. 
 
Results and discussion 
 
To improve the efficiency of the fragmentation of cytisine, we 
have explored the chemistry illustrated in Scheme 2 in a number 
of ways: (i) the conditions for C(6) lithiation must avoid 
metalation at other sites, see below. (ii) the variation of the N(3) 
substituent that is possible; this was N-methyl earlier but this is 
less attractive for downstream synthetic utility. (iii) the choice 
of electrophile (ideally employed in situ during the 
deprotonation step) used to trap the C(6) lithiated species (i.e. 
8) in order facilitate C(6)-N(7) cleavage. (iv) the conditions 
needed to achieve that critical transformation that also avoid 
heavy metals such as Hg(II). 
 
Revisiting C(6) lithiation of N-substituted cytisines. 
 
The original conditions used to lithiate N-methycytisine 7 
(which was trapped with Me2PhSiCl to give 9) had proceeded in 
48% yield.  Relatively straightforward variation of some of the 
basic reaction parameters allowed us to optimise this basic 
transformation to 83% in favour of C(6) lithiation and trapping.   
 
Scheme 3. Optimization of C(6) lithiation. Variables evaluated 
were substrate concentration, equivalents of LDA and 
Me2PhSiCl, and presence of TMEDA (key to a high yield of 9) 
Details are available in the Supplementary Information. 
Although we did observe yields of 9 of up to 90%, 83% reflected 
the yield obtained when competing lithiation (and trapping) at 
C(10) was suppressed.  The latter led to a C(10) silylation adduct 
12 (and this was exacerbated in the absence of TMEDA) and we 
also observed a (known)13b dimerization product 13 (Scheme 3).  
While LDA provided cleanly lithiation at C(6), Rouden observed 
C(10) (as well as competing C(9)) metalation and (in situ) 
silylation of N-methylcytisine 7 when a particularly bulky base 
(LiTMP) was used. We did see some level of C(10) lithiation with 
LDA and an analogous metalation (cf 12) within a simple 
pyridone (i.e. at C(4), pyridone numbering) has been reported 
by Katritzky.17 We evaluated N-Boc cytisine as a substrate for 
C(6) metalation but analysis of the crude reaction mixture 
(following reaction with LDA and silylation) indicated 
substitution at C(2) and/or (C(4) had occurred which is 
associated with Boc-directed metalation.18  
Use of N-benzyl cytisine 14 was more attractive both for 
downstream manipulations and because we did not observe 
competitive metalation (as 12) or dimer formation (as 13). 
Although Rouden has examined lithiation of 14, in our hands 
and using a more synthetically useful aryl-based chlorosilane 
(Me2PhSiCl), TMEDA (1 equiv.) did have an impact in terms of 
reaction efficiency and in particular suppressed a small amount 
of competing lithiation at C(10); 15 was isolated in 84% yield 
free of competing side products, with the mass balance 
accounted for by recovered 14 (Scheme 4).  
Scheme 4. C(6) Lithiation and silylation of N-benzylcytisine 14. 
 
Options around electrophilic component to facilitate C(6)-N(7) 
cleavage. 
 
Our original conditions for fragmentation of the cytisine tricycle 
to generate the piperidine unit associated with kuraramine 11 
involved silylation and Fleming-Tamao oxidation (using peracid 
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and stoichiometric Hg(OAc)2) followed by a reductive ring 
opening of hemiaminal 10 (Scheme 2). Closer inspection of this 
process indicated two competing reactions: desilylation of 9 to 
regenerate 7 and (ii) possible competing N-oxidation of the 
tertiary (N(3)) amine was suggested by MS analysis.  These 
oxidation conditions were modified to give a small increase in 
yield of 11 (from 38% to 47% from 8) by using a combination of 
H2O2 and peracetic acid (rather than peracetic acid alone) but 
this transformation still required Hg(OAc)2. All attempts, 
however, to achieve the conversion of 9 to 10 by other means 
e.g. KBr, AcOOH/AcOH; HBF4, then H2O2; KH, tBuOOH then 
TBAF, thereby avoiding mercury salts, failed.  This forced 
consideration of an electrophile that would offer an alternative 
cleavage mechanism. Lithiation followed by halogenation at 
C(6) was evaluated using a variety of halogen sources (Br2, I2, N-
bromosuccinimide, BrCCl2CCl2Br, CBr4) proved unproductive.  
However, diphenyl disulfide (not shown, but see Supplementary 
Information) and boron-based electrophiles were effective in 
situ traps for the C(6) lithio intermediate derived from 7 
(Scheme 5).  In the boron series, further optimisation using both 
N-methyl and N-benzylcytisine 7 and 14 respectively led to 
(OiPr)Bpin as the electrophile of choice, and adducts 16 and 17 
were obtained in 93 and 89% yields respectively.  While 
boronate esters 16 and 17 were relatively tolerant of 
chromatography, further purification was unnecessary.  Direct 
oxidation of the crude boronates (using NaBO3) followed by 
reduction (NaBH4) gave the piperidine core structures, (+)-
kuraramine 11 and the synthetically more flexible N-benzyl 
variant 18 in 32% and 52% overall yields (from 7 and 14) 
respectively. 
Scheme 5. C(6) borylation and ring cleavage. ‡ 
 
In summary, cytisine 6 is easily derivatised to the N-methyl and 
N-benzyl variants 7 and 14, each of which provides efficient 
access to the corresponding enantiomerically pure cis-3,5-
disubstituted piperidines 11 and 18 respectively. The results 
reported here serve to improve significantly the synthesis of (+)-
kuraramine 11 from N-methylcytisine and avoid heavy metal 
oxidants to mediate the key C(6)-N(7) bond cleavage.  Use of a 
boron-based electrophile, and specifically (OiPr)Bpin to trap the 
C(6) lithiated intermediate, was applicable to both the N-methyl 
and N-benzyl series. 
 
Elaboration of the piperidine scaffold; identification of 
protecting group arrays that enable selective site 
manipulation. 
 
Heterocyclic scaffolds, such as 11 and 18, offer significant 
potential with the N-Bn residue in particular cleavable under a 
variety of different reaction conditions.  Consequently, the 
majority of the remainder of this paper is focused on developing 
the potential of the N-benzyl piperidine 18 as the basis of a 
flexible heterocyclic core structure.  Our aim here is to 
demonstrate how the periphery of 18 can be functionalised in 
ways that would make this unit well suited to a general 
fragment-based drug discovery strategy, for the reasons 
articulated above.  We have explored chemistry around four 
specific sites illustrated in general scaffold A: via the piperidine 
nitrogen (N(1)), at C(3′) (in 18, a primary alcohol), and in three 
areas of the pyridone moiety, at C(3″) and C(4″) and across the 
lactam unit (N(1″) and C=O).  The latter is especially important 
to protect (deactivate) when pursuing functionalization of C(3′) 
(see below). Given the array of functional groups present within 
18, we have determined methods for differentiating at these 
different sites.  One consequence is that a series of protecting 
group arrays have been assessed and this is illustrated in 
Scheme 6. 
Selective N- and O-Boc protection in combination with O-
silylation provided a comprehensive set of options, which has 
allowed us to generate a number of differentially protected 
variants 19-24; this includes the fully deprotected variant 22.  
Additionally, the structure of the N,O-bis-Boc protected alcohol 
20 was solved by X-ray crystallographic analysis (see 
Supplementary Information).  The pyridone lactam underwent 
O-acylation in the presence of an excess of Boc2O, a protecting 
group array that is then cleavable under basic/nucleophilic 
conditions, see below. Further, the ability to manipulate 
selectively the pyridone nitrogen N(1″) is illustrated by 
N-methylation of 24 to give adduct 25. 
 
Elaboration at C(3’); variation of C(3’) oxidation level. 
 
That there is a requirement to protect/deprotect easily the 
pyridone moiety is exemplified attempts to derivatise the C(3′) 
primary alcohol (Scheme 7).  Reaction of N-Boc piperidine 19 
with phthalimide under Mitsunobu conditions in an attempt to 
access the 3’ amino variant led cleanly (and in essentially 
quantitative yield) to N-Boc cytisine 25.  
Of course, cis-disubstituted piperidine 19 is well set up to 
undergo intramolecular alkylation, a possibility that was both 
recognized and exploited elegantly in one of the very early 
syntheses of cytisine carried out 60 years ago by van Tamelen 
and Baran,19a,b and subsequently used in related contexts by 
others.19c-e 
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Scheme 6. Selective protection of piperidine, hydroxyl and pyridone moieties associated with 18. 
 
 
Scheme 7.  
 
We attempted to circumvent this issue via double mesylation of 
19 to generate intermediate 27 (not isolated, but assignment of 
a double mesylate was based on MS).  However, cyclisation still 
occured with 26 the only product observed on exposure of 27 
to azide or phthalate.  Clearly, the O-mesylate is labile in the 
presence of a good nucleophile but O-Boc protection solves this 
issue. Using intermediate 20, activation and phthalimide 
displacement at C(3′) followed by imide cleavage provided the 
C(3′) amino derivative 28 (Scheme 8).  Here, hydrazine also 
cleaves the O-Boc residue liberating the pyridone unit, but this 
is presumed to occur after nucleophilic displacement at C(3’).   
In addition, the scope of the C(3′) amino substituent can be 
extended using aldehyde 29 derived from 20 using Swern 
oxidation. 
Aldehyde 29 was not routinely isolated (to minimize any risk of 
epimerization) but used directly for reductive amination or 
further oxidation (see below).  Reductive amination using 
nucleophilic amines was generally accompanied by O-Boc 
cleavage under the reaction conditions (see 30a and 30b), and 
where (as in the case of an -amino ester) this does not occur, 
O-Boc cleavage is then readily achieved using aqueous 
ammonia (leading to 30c).  The latter is a generally applicable 
deprotection method20 and is illustrated further below.  Alcohol 
20 is also readily converted to the corresponding carboxylic acid 
31 in excellent overall yield and acid 31 offers access to a 
representative library of C(3′) derivatives (Scheme 9). 
Again, the pyridone unit is unmasked by O-Boc cleavage under 
nucleophilic conditions without disruption of other 
functionality to provide pyridones 32a-c. In addition, global 
deprotection of 31 is readily achieved to give the heterocyclic -
amino acid 33.   
Acid 33 is related to (S)-nipecotic acid (the parent piperidine-
based -amino acid), where 5-aryl substituted nipecotic acid 
derivatives have attracted medicinal chemistry interest.21  We 
had recognized a risk associated with C(3) epimerization of e.g. 
aldehyde 29. For that reason we secured the X-ray crystal 
structure of acid 31 (see Supplementary Information), which 
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confirmed both the (intact) cis-configuration and the presence 
of the O-Boc protected pyridine moiety.   
 
Scheme 8. Successful displacement at C(3’).  Yields of 30a-c are 
from alcohol 20. 
 
 
Scheme 9.  Ester/amide library based on carboxylic acid 31; 
global deprotection to provide acid 33. 
 
Elaboration at N(1). 
 
The final target site for substitution on this piperidine scaffold 
was at N(1).  This can be carried out in a number of ways, and 
we have simply illustrated the accessibility of this key position 
by N-debenzylation of 18 to give 22 (Scheme 6) as an isolable 
and versatile intermediate, followed by a representative 
reductive amination leading to the bis(piperidine) 34 (Scheme 
10).  This does, however, serve to show that protection 
elsewhere is not necessary in order to access N(1). 
Scheme 10.  Reductive amination at N(1). 
 
Regioselective functionalisation of the pyridone moiety; 
electrophilic bromination and Ir-catalyzed borylation. 
 
The remaining region of the piperidine scaffold that was of 
interest is associated with the pyridone unit.  Electrophilic 
halogenation of pyridones is well-established and leads 
predominately to 3-substitution, with the 5-halo isomer as 
(usually) the minor product.  Using N-bromosuccinimide, this 
pattern was observed with pyridone 19 (Scheme 11).   
Bromides 35 and 36 are readily separated (and easily 
differential by 1H NMR) and provide an obvious and very useful 
handle at C(3″) and C(5″).§  Access to C(4″) is also achievable 
using Ir-catalyzed borylation, as has been reported recently.22 In 
our hands, however, NH pyridones (e.g. 19) are not viable 
substrates for this C-H activation method.  N-Alkyl pyridones 
(e.g. 7) are, though, generally reactive and with O-Boc protected 
pyridines (i.e. 23) highly selective borylation at C(4’’) is 
observed.  
The scope and potential of this chemistry is illustrated in 
Scheme 11, and this includes two representative 
transformations of the intermediate boronate esters:  Suzuki 
coupling of adduct 37, followed by O-Boc cleavage (using basic 
ammonia) gave 38; Cu-mediated bromination and deprotection 
of adduct 39a gave 40, offering a reactant that complements 
the corresponding Bpin esters. It is useful to note that the low 
yield of 40 reflects the instability in solution of the intermediate 
bromide prior to O-Boc cleavage but this transformation has not 
been optimized. 
The chemistry outlined above serves to demonstrate the ability 
to manipulate the piperidine scaffold aligned to general 
structure A. This scaffold can be manipulated in a variety of 
distinct locations, using different transformations, and the only 
major requirement is the engagement of a suitable protecting 
group array that is primarily associated with moderating the 
reactivity of the pyridone unit.  That moderation, largely based 
on N- and O-(Boc) protection, is readily achieved.  Thus, we 
believe that the ready availability of (-)-cytisine and the 
efficiency with which the piperidine core unit can be revealed 
and then differentially manipulated makes this a potentially 
attractive starting point for a fragment-based discovery 
approach.   
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Scheme 11.  Pyridone functionalisation. 
 
Enhancing the complexity of (-)-cytisine via C(6) lithiation; 
Matteson homologation and Zweifel olefination. 
 
A key aspect of a fragment-based approach must be an ability 
to increase rapidly molecular complexity.  We have also 
explored additional avenues to address that issue where the 
goal has been to identify methods to introduce additional (and 
novel) complexity to the cytisine-based (tricyclic) precursor 
prior to any fragmentation and further functionalisation.  While 
these reactions do not contribute to extending the scope of the 
piperidine scaffold discussed earlier, they do provide access to 
novel cytisine variants that can be considered as alternative 
scaffold configurations and progenitors. 
Of particular relevance here was the potential associated with 
trapping a C(6) lithiated cytisine (see Scheme 2, intermediate 8) 
with a secondary boronate ester (e.g. EtBpin).  Our goal here 
had been to trigger a 1,2-migration sequence that would also 
serve to fragment the tricycle of cytisine and simultaneously 
create an addition stereocenter(*) at a key position on the 
periphery. The concept, which draws on previous work done 
within the Aggarwal group,23 is illustrated in Scheme 12. 
Using N-benzyl cytisine 14, lithiation and trapping with EtBpin 
appeared to generate the requisite borate intermediate 41 
based on 11B NMR which showed a signal at 6.3 ppm.  However, 
all attempts to achieve 1,2-migration using a range of Lewis 
acids failed.  Given that Bpin esters are sterically demanding, we 
also evaluated Et3B as a less demanding electrophile.  Again, 
“ate” formation (analogous to 41) occurred (as judged by 11B 
NMR) but no migration products could be detected.   
The most plausible explanation for these outcomes is that the 
pyridone N is not a sufficiently good leaving group to drive the 
migration step.  However, an appreciation of the stability of the 
pyridone moiety with respect to a 1,2-migration provided an 
opportunity to assess to other “ate”-based chemistries 
available using boronate ester 17.  
Boronate 17 undergoes efficient Matteson homologation24 to 
give boronate 42 in 89% yield. Oxidation of 42 provided primary 
alcohol 43 and the structure of the corresponding 4-
nitrobenzoate 44 confirmed the configuration at C(6) (see 
Supplementary Information).  A detailed 1H NMR analysis of 44 
was also carried (see Supplementary Information) which aided 
in the assignment of adduct 46 (see below). Zweifel 
olefination25 also involves generation of a stable borate 
intermediate and using boronate 17 proceeds very efficiently.  
Using a modified procedure developed in the Aggarwal 
group,25c exposure of 17 to vinyl Grignard (and this likely 
generates the triethenyl borate intermediate 45), followed by 
exposure to I2 in methanol gave the C(6) ethenyl adduct 46 in 
94% yield (Scheme 12).  The configuration at C(6) was confirmed 
by NOESY experiments (using 44 for comparison) and details of 
these studies are also available in the Supplementary 
Information 
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Scheme 12. Top: Attempt to couple 1,2-migration with tricycle 
cleavage. Bottom: C(6) alkenylation of N-benzyl cytisine 14.  
 
Conclusions  
 
In summary, C(6) metalation of N-alkyl cytisine derivatives 
provides a direct and versatile method of functionalization that 
allows for ring fragmentation to provide a synthetically flexible, 
enantiomerically pure piperidine based heterocyclic scaffold.  
Given the privileged nature of the piperidine ring within 
medicinal chemistry, we suggest that this is an attractive unit 
for the development of more complex heterocyclic ligands 
within the context of a fragment-based approach to drug 
discovery.  The potential of this functionalised piperidine 
scaffold has been exemplified using the N-benzylated variant 
18.  Critically it is possible to differentiate all key elements and, 
using C-H activation, to provide an additional functional handle 
within the pyridone unit. Attempts to induce a B-based 1,2-
migration as a means to increase the molecular complexity 
within the piperidone scaffold failed, however, the relative 
stability of the key intermediate (identified by a lack of 
reactivity) can be exploited.  Derivatives such as 43 and 46 that 
arise from this offer new opportunities for modification of the 
established nicotinic ligand profile of cytisine and studies in this 
area are underway. 
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